advertisement
advertisement
ADA Morning Huddle Logo

Treating migraines

Investigators may have uncovered whether triptans may be superior to newer migraine medications.

In a meta-analysis published in The BMJ, the investigators examined the outcomes of 137 randomized controlled trials involving 89,445 patients with migraines who received 17 oral monotherapy drugs or placebo.

Compared with the newer medications lasmiditan, rimegepant and ubrogepant, the investigators found that the drug eletriptan was the most effective triptan at alleviating pain within two hours followed by rizatriptan, sumatriptan and zolmitriptan.

In addition, triptans were associated with a favorable tolerability profile compared with the newer medications, which demonstrated a greater risk of side effects like dizziness, fatigue, sedation and paraesthesia. However, eletriptan had a higher risk of chest pain.

Despite the findings, clinicians were advised to carefully consider patients’ cardiovascular risks prior to prescribing triptans to treat migraines.

Read more: The BMJ

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.


© 2023 American Dental Association